A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2002
12/24/2002	US6498189 Suppression of inflammation and of lymph node entry by calmodulin antagonists; cell associated protein disulfide isomerase inhibitors; p-aminophenylarsine oxides
12/24/2002	US6498188 Administrating an n-chlorophenylcarbamate or an n-chloro-phenylthiocarbamate in combination with potentiator and/or chemotherapeutic agent
12/24/2002	US6498187 Fatty acid synthase inhibitors
12/24/2002	US6498185 Enzyme factor xa inhibitors
12/24/2002	US6498184 Use of the selective 5-ht2c receptor agonists 1-(6-chloro-5-(trifluoromethyl)-2-pyridinyl)-piperazine and (s)-(+)-3-((2,3-dihydro-5-methoxy-1h-inden-4-yl)oxy-pyrrolidine
12/24/2002	US6498183 Substituted indole sulfonamides as anitviral agents
12/24/2002	US6498181 Enhancing humoral immune response in combination with cancer therapy including surgery, radiation and immunotherapy
12/24/2002	US6498180 Such as 2-(3'-hydroxymethyl-2'-carboxycyclopropyl)glycine; modulating metabotropic glutamate receptor; treating disorders of central nervous
12/24/2002	US6498178 Inhibitors of IMPDH enzyme
12/24/2002	US6498177 Alpha 2 adrenergic receptor agonist; analgesic, sedative and anaesthetic agents
12/24/2002	US6498174 Agonists to peroxisome proliferator-activated receptors; modulating blood glucose and lipid levels; reducing dyslipidemia and hyperinsulinemia associated with impaired glucose tolerance or metabolic syndrome
12/24/2002	US6498173 Treatment of diseases based on acute or chronic obstruction of vessels and/or bronchi and/or inflammation
12/24/2002	US6498172 Prostaglandin agonists and their use to treat bone disorders
12/24/2002	US6498171 Hydroxyomeprazole compositions
12/24/2002	US6498170 4-((2s)-3-(1-(4-butoxy-benzenesulfonyl)-azetidin-3-ylamino)-2 -hydroxy- propoxy)-phenol for example; hypoglycemic agent; increasing lean meat to fat ratio in mammals
12/24/2002	US6498169 Cyclic amine compounds and pharmaceutical composition containing the same
12/24/2002	US6498168 Muscarinic antagonists
12/24/2002	US6498165 Pyrimidine compounds; prophylaxis and treatment of such as immune diseases, hyperproliferative disorders, cancer, angiogensis, atheroscelerosis, graft rejection, rheumatoid arthritis, psoriasis
12/24/2002	US6498164 Such as 1,3-dibenzyl-5-(phenyl- or 2-thienyl-acetyl)barbi-turic acid; malignant hypercalcemia, osteolytic diseases such as paget's disease, osteoporosis, articular rheumatism occurring in knees, shoulders, joints
12/24/2002	US6498162 Treating inflammatory and allergic diseases of respiratory tract and diseases of central nervous system
12/24/2002	US6498160 For therapy of emphysema, chronic bronchitis, asthma and allergic rhinitis
12/24/2002	US6498159 Such as 4-((3-chloro-4-methoxybenzyl)amino)-1-((4-hydroxy-4 -hydroxymethyl)piperidino)-6-phthalazine carbonitrile
12/24/2002	US6498158 Il-5 inhibiting 6-azauracil derivatives
12/24/2002	US6498157 Coatings and soaks for medical prosthetic devices comprising taurinamide derivatives and carboxylic acids and/or salts thereof
12/24/2002	US6498156 Diphenylazetidinone derivatives, process for their preparation, medicaments comprising these compounds and their use
12/24/2002	US6498155 Methods of treating thrombocytopenia
12/24/2002	US6498154 Cyclic regimens using quinazolinone and benzoxazine derivatives
12/24/2002	US6498153 Extended release growth promoting two component composition
12/24/2002	US6498152 Use of a farnesyl transferase inhibitor in the manufacture of a medicament for local administration to the vascular wall in the prevention of restenosis
12/24/2002	US6498151 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors
12/24/2002	US6498150 Low molecular weight cell, bone marrow and immune stimulants
12/24/2002	US6498149 Culturing human placental decidua derived cells with surface markers as positive cd57 and bright hla.dr; 1-dehydroxy-2-(1-guanine, 1-uracil or 1-(7-ketopurine))ribofuranose deri-vatives; reduced side effects
12/24/2002	US6498148 Immunization-free methods for treating antigen-stimulated inflammation in a mammalian host and shifting the host's antigen immune responsiveness to a Th1 phenotype
12/24/2002	US6498146 Erythromycin derivatives
12/24/2002	US6498145 Use of purified SDG as a hypotensive (vasodilator) agent
12/24/2002	US6498143 Method for assisting in differential diagnosis and treatment of autistic syndromes
12/24/2002	US6498142 Osteogenic protein-1 (op-1) and other members of the op-1 subfamily of the tgf-.beta. superfamily of growth factors
12/24/2002	US6498141 Method and apparatus for preparing an acellular red blood cell substitute
12/24/2002	US6497906 Anticholesterol, reduced menstrual bleeding
12/24/2002	US6497905 Aqueous solubility pharmaceutical formulations
12/24/2002	US6497904 Treatment of oncologic tumors with an injectable formulation of a golgi apparatus disturbing agent
12/24/2002	US6497896 Aqueous suspension; thermal sterilization
12/24/2002	US6497887 Delivery system for topical application to skin comprising freeze-dried, partially crosslinked polymeric gel membrane containing hyaluronic acid as disrupting agent, which can be returned to dissolvable gel upon application of wetting agent
12/24/2002	US6497886 1,3-bis-(N-lactamyl) propane and the pharmaceutical and cosmetic use thereof
12/24/2002	US6497885 Combination of the herb vitex agnus-castus (chasteberry) and antioxidants, including green tea, vitamin e or selenium, l-arginine, folic acid, vitamins b6 and b12, iron, zinc and magnesium; promoting ovulation
12/24/2002	US6497862 Composition for inhibiting body odor and uses thereof
12/24/2002	US6497859 Cooling agents, pharmaceutical compositions having cooling agents and processes for making and using same
12/24/2002	CA2278802C Ophthalmic compositions including glycerin and propylene glycol
12/24/2002	CA2252402C Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment
12/24/2002	CA2252039C Isatin derivatives as acetylcholinesterase inhibitors and analgesics
12/24/2002	CA2222133C Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
12/24/2002	CA2150812C Catechol diethers as selective pde iv inhibitors
12/24/2002	CA2134611C Process for preparing solid pharmaceutical dosage forms
12/24/2002	CA2131019C Nitrosation process
12/24/2002	CA2065462C Radiopharmaceutical bacteriostats
12/24/2002	CA2054339C 3-amidoindolyl derivatives
12/24/2002	CA2038984C Hydroxymethyl-indolizidines and quinolizidines
12/23/2002	WO2002094290A1 Use of lps for treating intestinal inflammation processes
12/23/2002	CA2414288A1 Use of lps in the treatment of intestinal inflammatory processes
12/22/2002	CA2391078A1 Pharmaceutical compositions comprising drug and concentration-enhancing polymers
12/21/2002	CA2390966A1 Compound for the treatment of atherosclerotic-thrombotic pathological conditions
12/20/2002	WO2002000259A1 Remedial agent for anxiety neurosis or depression and piperazine derivative
12/20/2002	CA2413506A1 Remedial agent for anxiety neurosis or depression and piperazine derivative
12/20/2002	CA2360824A1 Antiviral agent for drug-resistant virus
12/19/2002	WO2002101385A1 In vivo bioreactors
12/19/2002	WO2002101357A2 Molecular signatures of commonly fatal carcinomas
12/19/2002	WO2002101048A2 NEW POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNα-7 GENE
12/19/2002	WO2002101045A2 Vanilloid receptor-related nucleic acids and polypeptides
12/19/2002	WO2002101043A2 Regulation of human ta4 receptor
12/19/2002	WO2002101005A2 A g-protein coupled receptor and uses therefor
12/19/2002	WO2002100886A1 Pyrrolidin-2-one derivatives as inhibitors of factor xa
12/19/2002	WO2002100880A1 Method for preparing oestrogen derivatives
12/19/2002	WO2002100879A1 Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives
12/19/2002	WO2002100877A1 Novel 2-alkoxyestradiol analogs with antiproliferative and antimitotic activity
12/19/2002	WO2002100865A1 Benzoxazepine derivatives and their use as ampa receptor stimulators
12/19/2002	WO2002100864A1 Pyrazolopyrazine compound and pharmaceutical use thereof
12/19/2002	WO2002100863A1 Corticotropin releasing factor antagonists
12/19/2002	WO2002100862A2 Novel substituted tetracyclic imidazole derivatives, processes for their preparation, pharmaceutical compositions comprising them and their use as a medicine
12/19/2002	WO2002100860A2 Heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as anti-bacterial agents
12/19/2002	WO2002100858A2 Quinuclidine-substituted heteroaromatic compounds as ligands at nicotinic acetylcholine receptors
12/19/2002	WO2002100857A1 Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease
12/19/2002	WO2002100856A1 Macrocycles useful in the treatment of alzheimer's disease
12/19/2002	WO2002100854A1 Lactone formulations and method of use
12/19/2002	WO2002100853A1 Pyrazole derivatives as hiv reverse transcriptase inhibitors
12/19/2002	WO2002100852A1 Benzothiophene compounds having antiinfective activity
12/19/2002	WO2002100851A2 Thiophene derivatives as antiviral agents for flavivirus infection
12/19/2002	WO2002100849A2 Novel nitriles useful as reversible inhibitors of cysteine proteases
12/19/2002	WO2002100848A1 Novel phenylalkyl diamine and amide analogs
12/19/2002	WO2002100847A2 Factor xa inhibitor
12/19/2002	WO2002100846A1 Compounds and methods for the treatment or prevention of flavivirus infections
12/19/2002	WO2002100845A1 Hv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
12/19/2002	WO2002100844A2 Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
12/19/2002	WO2002100843A1 Phenoxazine compounds, the compositions containing them and their medicinal uses
12/19/2002	WO2002100842A1 Sulfonyloxazolamines and their use as 5-ht6 ligands
12/19/2002	WO2002100838A1 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines as crf1 receptor modulators
12/19/2002	WO2002100836A2 Compounds, compositions and methods for modulating beta-amyloid production
12/19/2002	WO2002100835A1 Heterocyclic compounds having antitumor activity
12/19/2002	WO2002100832A1 Isoquinoline compounds having antiinfective activity
12/19/2002	WO2002100830A1 Pyrrolidine derivatives as factor xa inhibitors
12/19/2002	WO2002100828A2 Process for the production of zaleplon

1 ... 5612 5613 5614 5615 5616 5617 5618 5619 5620 5621 5622 5623 5624 5625 5626 5627 5628 5629 5630 5631 5632 ... 7860